US-based diagnostics technology manufacturer Boston Microfluidics has received $17.5m in a series A round led by venture capital firm Anzu Partners and backed by life sciences research services provider LabCorp.
Boston Microfluidics supplies blood collection devices that enable patients to take samples at home rather than relying on visits to a doctor’s surgery. LabCorp already offers Boston’s flagship product, Neotainer, as part of a consumer wellness testing service branded Pixel by LabCorp.
The series A cash will go to research and development, as Boston Microfluidics seeks to enhance its existing product while introducing new devices. It had previously secured about $2.9m in equity and debt financing over three rounds between 2007 and 2017, according to securities filings.
Brandon Johnson, Boston Microfluidics’ chief executive, said: “LabCorp has been a great strategic partner to help us start getting our device into the hands of consumers,
“And that is really just the beginning. We are looking forward to expanding our base to reach more people around the world, and creating new products to make it easier for them to collect high quality samples.”